Canc

Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy

Contributing Editor With over 200,000 new cases and 40,000 deaths per year, breast cancer undoubtedly qualifies as one of Americas most serious health problems. Recently, efforts to develop early detection methods and more effective therapy have made important progress. This is particularly...

Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer

NEW YORK, July 12, 2007 /PRNewswire-FirstCall/ -- ImCloneSystems Incorporated and Bristol-Myers Squibb Company todayannounced results from an open-label Phase III study of ERBITUX(R)(Cetuximab) plus a taxane and carboplatin in the first-linetreatment for metastatic non-small cell lung cancer (NSCLC). Thestudy did not meet its primary endpoint of progression-freesurvival (PFS) as assessed...

Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs

IRVING, Texas--(BUSINESS WIRE)--Jul 11, 2007 - The Journal of theAmerican Society of Clinical Oncology has published the earlyresults of a clinical study conducted by Dr. Siu-Fun Wong, and hercolleagues, which concluded that the topical gel, Regenecare(R),caused a statistically significant reduction in the pain anditching of a rash that results from the use of anti-cancer drugsknown as EGFR...

Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial

LONDON, 12 July 2007 - Cancer drug developer Antisoma plc(LSE: ASM, US OTC: ATSMY) today announces new data from its phaseII trial of ASA404 in recurrent, platinum-sensitive ovarian cancer.This trial compares patients receiving ASA404 plus chemotherapy(n=37) with patients receiving chemotherapy alone (n=38). The mainfindings are as follows: * There was no advantage in median time t...

Protox Announces Positive Clinical Data from Prostate Cancer Study

VANCOUVER, British Columbia, July 10, 2007 /CNW/ - ProtoxTherapeutics Inc. (TSX-V:PRX) today announced positivetop-line results from its Phase 1 clinical trial evaluating PRX302 in patients with localized, recurrent prostate cancerfollowing radiation failure. The trial results indicate thatPRX302 is safe and well tolerated and shows promising signsof therapeutic activity following a s...

Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting System's Success in Mouse Model Reported in Cancer Cell

HOUSTON, July 9, 2007 - A molecularly engineeredtherapy selectively embeds a gene in pancreatic cancer that shrinksor eradicates tumors, inhibits metastasis, and prolongs survivalwith virtually no toxicity, researchers from The University ofTexas M. D. Anderson Cancer Center report in the July 9 edition ofCancer Cell. "This vehicle, or vector, is so targeted and robust in itscanc...

MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial

MARTINSRIED/MUNICH, Germany, July 9, 2007-A virus that has beenspecifically designed by scientists to be safe to normal tissue butdeadly to cancer is showing early promise in a preliminary study,researchers said today at the ESMO Conference Lugano (ECLU),Switzerland. The virus, called NV1020, is a type of herpes simplex virusmodified so that it selectively replicates in virus cells...

Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer

- First prospective biomarker trial in non-small cell lung cancer - LOS ANGELES, July 09, 2007 /PRNewswire-FirstCall/ -- ResponseGenetics, Inc. today announced that positive Phase III clinicaldata published in the July 1 issue of the Journal of ClinicalOncology suggests that low expression of the biomarkerExcision-Repair Cross-Complementing 1 (ERCC-1) in patient biopsieswith advanced non-...

Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine

- Phase II Results Published in the Journal of Clinical Oncology - NEW YORK, July 06, 2007 /PRNewswire-FirstCall/ -- Results from aPhase II study - which will be published in the August 10, 2007issue of the Journal of Clinical Oncology (JCO) and are nowavailable as an Early Release Article at <a target="_blank" href="http://www.jco.org/">www.jco.org - demonstrate thatixabepilone, a Br...

Peer Reviewed Journal Article Indicates Repros' Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jul 5, 2007 - ReprosTherapeutics Inc. (NasdaqGM:RPRX) today announced that an articlehas been published in the July 1, 2007 issue of Oncology Reportsindicating a potential for a new approach to the treatment ofbreast cancer using Proellex. The article reviews the findings froma study conducted in an accepted in vivo rat model of breastcancer. The study...

Rosetta Genomics and Weizmann Institute Scientists Identify Role of microRNA in Cancer Suppression

Findings Published in Molecular Cell Show Potential of microRNAs asNovel Cancer Drug Targets REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, July 05, 2007/PRNewswire-FirstCall/ -- Rosetta Genomics Ltd , a leading microRNAcompany, announced today research published in the journalMolecular Cell by scientists from the Weizmann Institute of Scienceand Rosetta Genomics . The findings suggest...

From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials

PHILADELPHIA, July 3, 2007-- Ongoing therapeutic cancer vaccinetrials have yet to show evidence of vaccines spurring apatient’s immune system to shrink tumors -- yet patients whoreceive these vaccines in trials tend to live longer and respondbetter to subsequent treatment. In the July 1 issue of ClinicalCancer Research, a journal of the American Association for CancerResearch, a te...

Skin Rash Actually Signifies Better Outcomes for Pancreatic and Lung Cancer Patients

PHILADELPHIA, July 3, 2007-- – The appearance of arash in cancer patients treated with erlotinib (Tarceva) isstrongly associated with longer survival, according to researchersfrom the drug’s developer, OSI Pharmaceuticals, Inc. This isnot the first time that rash has been associated with a survivaladvantage with EGFR inhibitors – a class of drugs whichincludes erlotinib...

Researchers Discover Method for Identifying How Cancer Evades the Immune System

PHILADELPHIA, July 3, 2007-- One of the fundamental traits of atumor – how it avoids the immune system – might becomeits greatest vulnerability, according to researchers from theUniversity of Southern California. Their findings,demonstrated in human breast and colorectal cancers, indicate thata technique for determining a tumor’s “immunesignature,” could be...

Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics

PHILADELPHIA, July 3, 2007 ? Researchers in Slovakia havebeen able to derive mesenchymal stem cells from human adipose, orfat, tissue and engineer them into “suicide genes” that seek out and destroy tumors like tiny homing missiles. This gene therapy approach is a novel way to attack smalltumor metastases that evade current detection techniques andtreatments, the researchers...

Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast Cancer Risk Prediction in Women with Atypia

ROCHESTER, Minn., July 2, 2007-Women with at least three sites ofcellular atypia in breast tissue are nearly eight times more likelythan average women to develop breast cancer, according to findingsof a Mayo Clinic Cancer Center led study of women with atypicalhyperplasia. The findings are published in the July 1 issue of theJournal of Clinical Oncology. Several previous studies have show...

Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers

WASHINGTON, January 29, 2007 /PRNewswire-USNewswire/ -- RearAdmiral Timothy Ziemer (U.S. Navy, retired), the President'sMalaria Coordinator, announced his intent to name Dr. BernardNahlen to serve as Deputy Coordinator of the President's MalariaInitiative (PMI). Dr. Nahlen is a Commissioned Officer in the U.S.Public Heath Service and has most recently served as SeniorAdvisor, Monitoring...

Vaccine Can Prevent Cervical Cancer and Precancerous Lesions

LONDON, June 28, 2007--A cervical cancer vaccine has shown 90%efficacy for prevention of cervical cancer and precancerous lesionsassociated with the human papillomavirus (HPV) types targeted bythe vaccine, conclude authors of an Article published early Onlineand in the upcoming issue of The Lancet. HPV types 16 and 18 account for 70% or morecases of cervical cancer worldwi...

RTA 402 Shown to Protect Animals Against Toxicities of Standard Cancer Treatments

IRVING, Texas--(BUSINESS WIRE)--Jun 29, 2007 - ReataPharmaceuticals, Inc. today announced the presentation of newpreclinical data showing their lead anti-cancer agent, theSynthetic Triterpenoid RTA 402, is effective at protecting againstcommon toxicities caused by traditional cancer treatments. Thisdata was presented at the annual meeting of the MultinationalAssociation of Supportive Care i...

European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGene's Cancer-Killing Virus in Press Conference

* Presentation of efficacy trends from ongoing phase I/II trialof oncolytic HSV * Poster selected by ESMO for presentation inpress conference MARTINSRIED, Germany, June 29, 2007.--The biotech companyMediGene AG (Frankfurt, Prime Standard: MDG) announces that a casereport from the ongoing clinical trial of MediGene's cancer killingvirus will be presented in a press conferen...

Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types

Results also show significant additional protection againstinfection with virus types beyond 16 and 18 with the GSK cervicalcancer candidate vaccine PHILADELPHIA, June 27, 2007 /PRNewswire-FirstCall/ -- Resultsfrom an interim analysis of a Phase III study show thatCERVARIX(R), the GlaxoSmithKline cervical cancer candidate vaccine,provides up to 100 percent protection against advanced prec...

Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma

WORCESTER, Mass.--(BUSINESS WIRE)--Jun 28, 2007 - BiovestInternational, Inc. (OTCBB: BVTI), a majority owned subsidiary ofAccentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), announced on June27, 2007 blinded interim data from the start of its fast-trackedpivotal Phase 3 clinical trial of BiovaxID(TM) for Non-Hodgkin'slymphoma (NHL) from September 2000 through June 2006. This interimblinded dat...

Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer

WAILEA, Hawaii and SUNNYVALE, Calif., June 27, 2007/PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announcedpreliminary results from two open-label, multi-center Phase 2clinical trials supporting the potential use of Xcytrin(R)(motexafin gadolinium) Injection, the company's lead productcandidate, in combination with Alimta(R) (pemetrexed) and incombination with Taxotere(R) (docetaxel...

Publication Confirms that EpCAM, the Target for Two of Micromet's Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers

BETHESDA, Md., June 26, 2007 /PRNewswire-FirstCall/ -- Micromet,Inc. , a biopharmaceutical company focusing on the development ofnovel, proprietary antibody-based products for cancer, inflammatoryand autoimmune diseases, announced that a study published recentlyin the Proceedings of the National Academy of Sciences (1) supportsthe findings of several other studies that EpCAM (CD326), whic...

Neuroblastoma Expert Reviews Progress and Challenges in Fighting Difficult Pediatric Cancer

PHILADELPHIA, June 25, 2007 /PRNewswire-USNewswire/ -- Childhoodcancers are fortunately rare, but among them, neuroblastoma is aspecial case, accounting for 7 percent of all childhood cancers,but 15 percent of childhood cancer deaths. It typically occurs as asolid tumor in the abdomen, but also in the neck, chest, andpelvis, developing in the network of the body's sympathetic nervoussyst...

Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer

Study Fails to Meet Primary Endpoint of Improvement in OverallSurvival WESTMINSTER, Colo., June 19, 2007 /PRNewswire-FirstCall/ --Allos Therapeutics, Inc. today announced top line results fromENRICH, the Company's pivotal Phase 3 study of Efaproxyn (efaproxiral) plus whole brain radiation therapy (WBRT) in womenwith brain metastases originating from breast cancer. The studyfailed to achi...

First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex

Anastrozole (ArimidexTM) improves overall survival inpostmenopausal women with early breast cancer receiving treatmentwith tamoxifen – Survival benefit demonstrated for an AI over tamoxifenin a single trial – LUTON, England, Friday 15 June 2007: Analysis of the entirepopulation of a single trial has demonstrated that survival inearly breast cancer can be signific...

Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care

NEWTON, Mass.--(BUSINESS WIRE)--Jun 18, 2007 - NovelosTherapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical companyfocused on the development of therapeutics to treat cancer andhepatitis, today announced encouraging results in an ongoingDana-Farber/Partners Cancer Care (DF/PCC) Phase 2 trial of NOV-002in combination with carboplatin in platinum-resistant ovariancancer patients. To date, 10...

Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen

Survival Benefit Demonstrated for an AI Over Tamoxifen ina Single Trial LUTON, UK, Friday 15 June 2007: Analysis of the entirepopulation of a single trial has demonstrated that survival inearly breast cancer can be significantly improved by switching fromtamoxifen to anastrozole (Arimidex). An analysis of the'Arimidex'-'Nolvadex 95' (ARNO 95) study, published online in TheJourna...

Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood

Preclinical Studies Show 227Th-rituximab More Effective atKilling CD20-Positive Lymphoma Cells Than 90Y-tiuxetan-ibritumomab(Zevalin) OSLO, Norway, 14 June 2007 - Algeta ASA (OSE: ALGETA), theNorwegian cancer therapeutics company, announces that a researchpaper showing the potential of its TH-1 technology for targetedcancer therapy has been published by the leading medical journal,...

Women Well-Informed About Breast Cancer, Yet Lacking Knowledge About Current Treatments, New Survey Finds

-- CancerCare offers five questions to help womenlearn about breast cancer therapy advances -- NEW YORK, June 12, 2007 – According to a newGfK Roper Public Affairs survey sponsored by CancerCare, a nationalnonprofit cancer support organization, while the majority (76percent) of women surveyed said they know at least a fair amountabout breast cancer...

Geron's Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial

MENLO PARK, Calif.--(BUSINESS WIRE)--Jun 12, 2007 - GeronCorporation's (Nasdaq:GERN) telomerase inhibitor cancer drug,GRN163L, has demonstrated good pharmacokinetics and tolerability inits ongoing Phase I/II trial involving patients with chroniclymphocytic leukemia (CLL), according to data presented today byAlan Colowick, M.D., M.P.H., the company's president, oncology, atthe Pan Pacific Ly...

Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association

Interim Data from Phase 1 Clinical Trial of SNS-595 in AcuteLeukemia Demonstrates Additional Clinical Activity SOUTH SAN FRANCISCO, Calif., June 11, 2007/PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. presentedpositive data from clinical studies of two of the company'santi-cancer product candidates, SNS-595 and SNS-032, at the 12thCongress of the European Hematology Association (E...

Trial Results with Intranasal Fentanyl Hold Promise for Treatment of Breakthrough Pain in Cancer

<p style="MARGIN: 0in 0in 0pt; LINE-HEIGHT: 150%; mso-hyphenate: none">BUDAPEST, Hungary, June, 7, 2007--A pioneering nasal spraycould stop thousands of patients with cancer from sufferingunnecessary pain; it was reported today1 at the 10th Congress ofthe European Association for Palliative Care, Budapest, 7–9June. The study investigated whether this first in class novelformulation c...

ApoCell's Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy

HOUSTON--(BUSINESS WIRE)--Jun 7, 2007 - ApoCell, Inc. presented theresults of a study conducted by researchers at the University ofChicago and ApoCell at the 2007 annual meeting of the AmericanSociety of Clinical Oncology (ASCO) held in Chicago in early June.The study showed that ApoCell's advanced pharmacodynamic biomarkerassay technology provides reliable predictive data of clinicalrespon...

Clinical Results From EntreMed's Panzem NCD and Taxol Breast Cancer Study Presented at ASCO

Safety, Efficacy and Markers Demonstrated in Combination Trial ROCKVILLE, Md., June 06, 2007 /PRNewswire-FirstCall/ --EntreMed, Inc. , a clinical-stage pharmaceutical company developingtherapeutics primarily for the treatment of cancer and inflammatorydiseases, announced the presentation of interim data from the Phase1b study with Panzem(R) NCD (2ME2 or 2-methoxyestradiol) incombination w...

Immunomedics Reports Initial Clinical Results With Hpam4 For Pancreatic Cancer Therapy

- Results Presented at Society of Nuclear Medicine Annual Meeting - WASHINGTON, June 05, 2007 /PRNewswire-FirstCall/ --Immunomedics, Inc. , a biopharmaceutical company focused ondeveloping monoclonal antibodies to treat cancer and other seriousdiseases, today announced that initial results from a Phase I studywith the Company's humanized anti-MUC1 monoclonal antibody (hPAM4),labeled with...

Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients

CHICAGO, DARMSTADT, Germany, June 5, 2007 – Thisyear’s American Society of Clinical Oncology (ASCO) meetingin Chicago sees a wealth of promising new data presented regardingMerck KGaA’s targeted cancer therapy Erbitux®(cetuximab), further demonstrating the consistent efficacy andversatility of this agent in both first-line and subsequenttreatment of metastatic color...

Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age

New Study Results Show Antibodies Against Cancer-Causing VirusTypes 16 & 18 That Are At Least Ten Times Greater Than NaturalInfection Levels CHICAGO, June 05, 2007 /PRNewswire/ -- New Phase III data showthat at 18 months after the first of a three-dose regimen, 100percent of women up to age 55 vaccinated with the GlaxoSmithKline(GSK) cervical cancer candidate vaccine had antibodies pr...

Clinical Trial Results Change Standard of Care for Pancreatic Cancer Patients, Future Therapies Discussed

CHICAGO, June 05, 2007 /PRNewswire-USNewswire/ -- The BarbaraAnn Karmanos Cancer Institute's Philip A. Philip, M.D., Ph.D.F.R.C.P., professor of medicine and oncology, presented the outcomeof one of the largest randomized phase III pancreas cancer clinicaltrials in North America and chaired an education session about thefuture of pancreatic cancer therapies at the American Society ofClin...